Ceryvyn Therapeutics Ltd ADR (OPTEY)

Currency in USD
0.027
+0.004(+17.17%)
Closed·
Advertisement
OPTEY is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.0220.027
52 wk Range
0.0023.170
Key Statistics
Prev. Close
0.023
Open
0.022
Day's Range
0.022-0.027
52 wk Range
0.002-3.17
Volume
3.11K
Average Volume (3m)
31.34K
1-Year Change
-99.2097%
Book Value / Share
0.02
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
OPTEY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1.000
Upside
+3,603.70%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 1.000
(+3,603.70% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
03/06/2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare OPTEY to Peers and Sector

Metrics to compare
OPTEY
Peers
Sector
Relationship
P/E Ratio
0.1x−8.1x−0.4x
PEG Ratio
0.00−0.060.00
Price/Book
0.5x2.2x2.6x
Price / LTM Sales
−884.0x20.3x3.0x
Upside (Analyst Target)
-236.8%51.9%
Fair Value Upside
Unlock−2.1%9.4%Unlock

Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company’s pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
73.72M5.39%1.70M
Other Institutional Investors
482.07M35.24%11.09M
Public Companies & Retail Investors
812.19M59.37%18.68M
Total
1.37B100.00%31.46M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
The Carlyle Group Inc.7.05%96,466,5912,219
Ocelot SPV LP7.05%96,466,5912,219

People Also Watch

1.16
ONEG
+1.75%
1.1100
IGSC
-7.50%
4.050
PODC
+6.58%
1.190
BRCC
-0.83%

FAQ

What Is the Ceryvyn ADR (OTC Markets: OPTEY) Share Price Today?

The Ceryvyn ADR stock price today is 0.027 USD.

What Stock Exchange Does Ceryvyn ADR (OPTEY) Trade On?

Ceryvyn ADR is listed and trades on the OTC Markets.

What Is the Ticker (Stock Symbol) for Ceryvyn ADR?

The stock symbol (also called a 'ticker') for Ceryvyn ADR is "OPTEY."

What Is the Current Ceryvyn ADR Market Capitalisation?

As of today, Ceryvyn ADR (OTC Markets: OPTEY) market cap is 9.490M USD.

What Is Ceryvyn ADR's (OPTEY) Earnings Per Share (TTM)?

The Ceryvyn ADR EPS is currently 0.232 (Trailing Twelve Months).

When Is the Next Ceryvyn ADR Earnings Date?

Ceryvyn ADR's next earnings report will be released on 28/08/2026.

Is OPTEY a Buy or Sell From a Technical Analyst Perspective?

Based on today's Ceryvyn ADR moving averages and other technical indicators, the daily buy/sell signal for OPTEY stock is Strong Sell.

How Many Times Has Ceryvyn ADR Stock Split?

Ceryvyn ADR has split 1 times. (See the OPTEY stock split history page for full effective split date and price information.)

How Many Employees Does Ceryvyn ADR Have?

Ceryvyn ADR has 33 employees, based on their latest Companies House report.

What is the current trading status of Ceryvyn ADR (OTC Markets: OPTEY)?

As of 09/07/2026, Ceryvyn ADR (OPTEY) is trading at a share price of 0.027 USD, with a previous close of 0.023 USD. The stock has fluctuated within a day range of 0.022 USD to 0.027 USD, while its 52-week range spans from 0.002 USD to 3.170 USD.

What Is Ceryvyn ADR (OPTEY) Price Target According to Analysts?

The average 12-month price target for Ceryvyn ADR is 1.000 USD, with a high estimate of 1 USD and a low estimate of 1 USD. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +3,603.70% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.